CD19 and leukemia: A smaller study carried out by Singh and colleagues at CHOP and University of Pennsylvania utilizing a similar CD22/4-1BB-based CAR as the NCI study included five children and three adults who had previously all undergone CD19-directed therapy and most of whom had CD19-negative leukemia (NCT02588456 and NCT02650414) [50].